PGI25 Cost Effectiveness of Boceprevir Plus Peginterferon Alpha and Ribavirin Versus Peginterferon Alfa Plus Ribavirin in the Treatment of Chronic Hepatitis C (CHC) in Previously Untreated Genotype I Patients
Jun 1, 2012, 00:00
10.1016/j.jval.2012.03.752
https://www.valueinhealthjournal.com/article/S1098-3015(12)00817-0/fulltext
Title :
PGI25 Cost Effectiveness of Boceprevir Plus Peginterferon Alpha and Ribavirin Versus Peginterferon Alfa Plus Ribavirin in the Treatment of Chronic Hepatitis C (CHC) in Previously Untreated Genotype I Patients
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)00817-0&doi=10.1016/j.jval.2012.03.752
First page :
A139
Section Title :
Gastrointestinal Disorders
Open access? :
No
Section Order :
230